-
2025-521035-37-00
5
2026-03-02
Immune system diseases
-
2025-522853-21-01
9
2026-02-27
Active, treatment refractory, ANCA-IgG-positive associated vasculitis
-
2024-516411-24-00
5
2026-02-25
Insomnia Disorder
-
2024-511101-28-00
4
2026-02-24
Episodic Migraine
Chronic Migraine
-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2024-511362-37-00
5
2026-02-18
Non squamous non-small cell lung cancer (NSCLC)
-
2025-521805-41-00
5
2026-02-18
Patients with HER2-positive, locally advanced or metastatic breast can
-
2024-516356-18-00
5
2026-02-17
Atherosclerotic cardiovascular disease (ASCVD)
-
2025-521849-25-00
4
2026-02-17
Chronic Graft-Versus-Host Disease
-
2025-522703-14-00
5
2026-02-17
"Moderate to severe obstructive sleep apnea (OSA) in adults living wit
-
2024-516966-12-00
4
2026-02-13
Alzheimer’s disease
-
2025-522640-41-00
4
2026-02-13
Asthma
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2024-515765-34-00
5
2026-02-04
English
First-line extensive-stage small-cell lung cancer (ES-SCLC)
-
2025-521636-10-00
4
2026-02-04
Progressive Forms of Multiple Sclerosis (PMS)
-
2025-522370-36-00
4
2026-02-02
Moderate to Severe Atopic Dermatitis
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2025-521717-67-00
3
2026-01-29
Acute myeloid leukemia
-
2025-520688-42-00
4
2026-01-27
Amyotrophic Lateral Sclerosis (ALS)
-
2025-521043-20-00
10
2026-01-27
Neuroendocrine tumors
-
2025-521768-36-00
9
2026-01-27
Metastatic colorectal cancer
-
2025-522400-24-00
10
2026-01-27
Metastatic urothelial cancer
-
2025-523995-21-00
3
2026-01-27
Healthy participants
-
2025-522216-17-00
1
2026-01-26
Atopic Dermatitis